Drug Profile
Olodaterol - Boehringer Ingelheim
Alternative Names: BI-1744; BI-1744-CL; BI1774CL; Olodaterol hydrochloride; Striverdi RespimatLatest Information Update: 21 Nov 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Amines; Benzoxazines; Bronchodilators; Ketones; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease
- Discontinued Asthma
Most Recent Events
- 07 Sep 2021 Discontinued - Phase-II for Asthma in Germany, Canada, France, USA (Inhalation) (Boehringer Ingelheim pipeline, September 2021)
- 07 Sep 2021 Discontinued - Phase-III for Chronic obstructive pulmonary disease in Argentina, Brazil, China, South Africa, Taiwan, Hong Kong, India, South Korea, Malaysia, Philippines, Japan, Japan and Thailand (Inhalation) (Boehringer Ingelheim pipeline, September 2021)
- 28 Oct 2014 Efficacy and adverse events data from the ANHELTO 1 and 2 phase III trials in Chronic obstructive pulmonary disease presented at the 80th Annual Meeting of the American College of Chest Physicians (ACCP-2014)